AxioMx announced that it has received a Phase I Small Business Innovative Research (SBIR) grant that will fund the development of a technique to rapidly convert single-chain variable fragments (scFvs) to full-length immunoglobulin G (IgG) molecules, the most common form of antibody used in research today.

“Although some of our customers prefer a scFv as their deliverable, many others request IgGs,” said Chris McLeod, president and CEO of AxioMx. “The funding we have received will support implementing a new method that can convert scFv antibodies into IgG molecules quicker and at lower cost than any other technique available.”